In an orthotopic GBM mouse model, SAFit2 showed an anti-tumor effect, as assessed by reductions in tumor volumes, caspase activation and attenuated expression levels of PD-L1 and the mesenchymal marker vimentin. Here, CD274 is linked to glioblastoma.